Call +41-61-926-60-40 Fax +41-61-926-60-49

MCC950 . sodium salt

AG-CR1-3615-M001 1 mg INQ
AG-CR1-3615-M005 5 mg INQ
AG-CR1-3615-M010 10 mg INQ
Select size:

* Required Fields

Add to Cart
Call +41-61-926-60-40
Fax +41-61-926-60-49
Contact Us!

Additional Information

Product Data
Synonyms MCC950; CP-456,773; CRID3; 1-(1,2,3,5,6,7-Hexahydro- s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea
Formula C20H23N2NaO5S
MW 426.5
CAS 256373-96-3
Purity ≥97% (HPLC)
Appearance Crystalline solid.
Solubility Soluble in water, DMSO, dimethyl formamide or ethanol.
Identity Determined by 1H-NMR.
Product Type Chemical
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download Document Download
Related Products

Product Description

  • Potent, selective and orally available NLRP3 inflammasome inhibitor.
  • Blocks the release of IL-1β in macrophages primed with LPS and activated with ATP or nigericin, but it does not inhibit NLRP1, NLRC4, AIM2, TLR2 signaling or priming of NLRP3.
  • Prevents oligomerization of ASC in cells stimulated with LPS and nigericin.
  • Active in vivo, blocking the production of IL-1β and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome (CAPS). Also active in ex vivo samples from individuals with Muckle-Wells syndrome.
  • Potential therapeutic agent for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases.

Product References

  1. Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing: R.E. Laliberte, et al.; J. Biol. Chem. 278, 16567 (2003)
  2. Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methylethyl)furan-2-sulfonyl]urea, an antiinflammatory agent: F.J. Urban, et al.; Synth. Commun. 33, 2029 (2003)
  3. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes: R.C. Coll, et al.; PLoS One 6, e29539 (2011)
  4. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases: R.C. Coll, et al.; Nat. Med. 21, 248 (2015)
  5. Taming the inflammasome: M. Levy, et al.; Nat. Med. 21, 213 (2015)
  6. The Nlrp3 inflammasome admits defeat: C.J. Gross & O. Gross; Trends Immunol. 36, 323 (2015)
No reviews for this product yet.